Kailera Therapeutics (NASDAQ:KLRA) Stock Price Up 9.8% – What’s Next?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price shot up 9.8% on Wednesday . The company traded as high as $20.37 and last traded at $20.36. 219,072 shares changed hands during trading, a decline of 64% from the average session volume of 610,344 shares. The stock had previously closed at $18.55.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KLRA. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. TD Cowen began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price for the company. Zacks Research upgraded Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. William Blair assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “outperform” rating for the company. Finally, Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Up 5.3%

The firm’s 50 day simple moving average is $22.01.

Insider Activity

In other news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the stock in a transaction dated Monday, April 20th. The stock was bought at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the purchase, the insider directly owned 10,776,820 shares of the company’s stock, valued at $172,429,120. This represents a 4.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrew T. Kaplan acquired 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 10,460,938 shares of company stock valued at $167,375,008 over the last quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.